Refining CAR-NK Design - Poll - MDSpire

Refining CAR-NK Design

Preclinical findings suggest that receptor design and timed kinase inhibition could help strengthen next-generation cell therapies.

March 4, 2026
2 min

The Medicine Maker

Share

Original Source(s)

The Medicine Maker

Refining CAR-NK Design

March 4, 2026

Related Content

Bone Marrow Transplantation

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

by Yetian Dong, Tingting Yang, Mengyu Zhao, Fengmei Song, Rongrong Chen, Mingming Zhang, Ruimin Hong, Jingjing Feng, Shan Fu, Pingnan Xiao, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu
August 20, 2025

Frontiers In Immunology

A clinical-grade automated platform for the manufacturing of CAR-γδ T cells for immunotherapy

Frontiers In Oncology

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

by Chengqian Chen, Wei Guo, Xiaoyu Song, Xin Wan, Zhaoxia Li, Haotian Wang, Ou Bai
May 29, 2026